Structure of the kinase domain of human RIPK2 in complex with ponatinib

3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide

Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.

RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2

CARD-CONTAINING INTERLEUKIN-1 BETA-CONVERTING ENZYME-ASSOCIATED KINASE, CARD-CONTAINING IL-1 BETA ICE-KINASE, RIP-LIKE-INTERACTING CLARP KINASE, RECEPTOR-INTERACTING PROTEIN 2, RIP-2, TYROSINE-PROTEIN KINASE RIPK2, RIPK2

MGHHHHHHSSGVDLGTENLYFQSMSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDV
LREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLL
HHDLKTQNILLDNEFHVKIADFGLSKWCMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVL
SRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFL
EAVIQLKKTKLQSV

HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. U VALUES WITH TLS ADDED